The approval comes amidst rumours of a potential private equity buyout of the Canadian company, whose parent company has ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has ...

Bausch + Lomb said enVista Envy intraocular lenses will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. The company is in the process of seeking ...

Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...

Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...

The Lopez-led Asian Eye Institute announced Monday that two of its most accomplished doctors were recognized by top ...

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

Cataracts, a common eye condition that clouds vision and hampers daily activities, can now be treated with innovative ...

Good news is, Medicare does cover necessary cataract surgery including the removal of the cataract and the addition of a ...

Most people over age 60 eventually get cataracts. This common condition typically starts very slowly, so those who don’t have regular eye exams may not realize what’s going on inside their eyes.